Indegene Limited — Capital/Financing Update 2026

Jan 1, 2026

INDGN/SE/2025-26/90

January 01, 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India. Trading symbol: INDGN

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Amalgamation of two step down subsidiaries of the Company

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Company’s step down subsidiaries, Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada), both entities being 100% held by Indegene, Inc. USA (wholly owned subsidiary of Indegene Limited) have amalgamated on January 01, 2026 to form Indegene Healthcare Canada Inc.

The disclosure as required under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is mentioned in “Annexure-I”.

The above information is being made available on the website of the Company at https://www.indegene.com/.

This is for your information and records.

Yours Sincerely,

For Indegene Limited

Srishti Digitally signed by Srishti Ramesh Ramesh Kaushik Date: 2026.01.01 Kaushik 19:33:44 +05'30'

Srishti Ramesh Kaushik

Company Secretary and Compliance Officer

==> picture [132 x 41] intentionally omitted <==

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy

Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777 www.indegene.com

CIN: L73100KA1998PLC102040

Annexure - I

Sr. No.	Particulars	Description
1.	Name of the entity(ies) forming part of the amalgamation / merger, details in brief such as, size, turnover etc.	Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada) to form Indegene Healthcare Canada Inc. The projected revenue for FY25-26: Indegene Aptilon Services, Inc.- CAD 1,375,000 Trilogy Writing & Consulting Inc.– CAD 5,400,000
2.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	Yes
3.	Area of business of the entity(ies)	Trilogy - medical writing and regulatory documentation services for the pharmaceutical and life-science industries. Indegene - digital-first life-sciences commercialization, providing technology-enabled services to support biopharmaceutical and medical-device companies in bringing therapies to market and engaging healthcare professionals and patients.
4.	Rationale for amalgamation / merger	Internal restructuring
5.	In case of cash consideration – amount or otherwise share exchange ratio.	No consideration
6.	Brief details of change in shareholding pattern (if any) of listed entity	None